期刊文献+

原发灶不明颈部淋巴结转移癌的诊断与综合治疗 被引量:1

Diagnosis and combined modality treatment of cervical lymph node metastasis from an unknown primary
原文传递
导出
摘要 原发灶不明颈部淋巴结转移癌并不少见,但至今未建立起必要的诊断程序。对于不明原发灶患者的综合治疗方法主要包括放射治疗和手术治疗,但始终存在争议。正电子发射断层显像(PET)以及分子生物学的发展提高了诊断的精确性,综合治疗的模式有了一定进展。 Cervical metastasis carcinoma of unknown primary is not uncommon. No established concept exists for the necessary procedures of diagnosis. The combined modality therapy for patients in whom no primary tumor is found includes surgery and radiotherapy, but there is still controversy. The development of PET and molecular biology enhances the accuracy of diagnosis. The pattern of combined modality therapy is now in progress.
出处 《国际肿瘤学杂志》 CAS 2008年第2期119-121,共3页 Journal of International Oncology
关键词 未知原发灶 头颈部肿瘤 诊断 综合疗法 Unknown primary Head and neck neoplasms Diagnosis Combined modality therapy
  • 相关文献

参考文献18

  • 1Dowell JE. Cancer from an unknown primary site. Am J Med Sci, 2003, 326( 1 ) :35-46.
  • 2Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology? Oncologist, 2007, 12 (4) :418-425.
  • 3Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: From autopsy to microarray. Eur J Cancer, 2007, 43 (14) :2026-2036.
  • 4Imamura S, Suzuki H. Head and neck metastases from occult abdominal primary site: a case report and literature review. Acta Otolaryngol, 2004, 124(1) :107-112.
  • 5Schmalbach CE, Miller FR. Occult primary head and neck carcinoma. Curr Oncol Rep, 2007, 9(2) :139-146.
  • 6Issing WJ, Taleban B, Tauber S. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol, 2003, 260(8) :436-443.
  • 7Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer, 2004, 101 ( 11 ) :2641-2649.
  • 8Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET/CT - initial experience. Radiology, 2005, 234( 1 ) :227-234.
  • 9Wartski M, Le Stanc E, Gontier E, et al. In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET-CT. Nucl Med Commun, 2007, 28(5) :365-371.
  • 10Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with ^18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging, 2006, 50 ( 1 ) : 15-22.

同被引文献13

  • 1Sere P, Sawyer M, Hanson J, et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site. A population-based study.Cancer,2006,106:2058-2066.
  • 2Jerusalem G, Rofive A, Ancion G, et al.Diagnostic and therapeutic management of carcinoma of unknown primary:radio-imaging investigations.Ann Oncol,2006,17:x168-x176.
  • 3Seve P, Ray-Coquard I, Trillet-Lenoir V, et al.Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.Cancer,2006,107:2698-2705.
  • 4Schneider BJ, El-Rayes B, Muler JH, et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknowm primary site.Cancer,2007,110:770-775.
  • 5Fizazi K.Treatment of patients with specific subsets of carcinoma of an unknown primary site. Ann Oncol,2006,17:x177-x180.
  • 6Van de Wouw A J, Jansen RL, Griffioen AW, et al. Clinical and analysis of patients with unknown primary rumour. A search for prognostic factors in UPT. Anticancer Res, 2004,24:297-301.
  • 7Burqers JA, Damhuis RA. Prognostic factors in malignant mesothelioma. Lung Cancer,2004,45:S49-54.
  • 8Bendardaf R, Lamlum H, Pyhonen S. Prognostic and predictive molecular markers in eolorectal carcinoma. Anticancer Res,2004,24:2519-2530.
  • 9Culine S, Lortholary A, Viogt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase Ⅱ study - trial for the French Study Group on Carcinoma of Unknown Primary (GEFCAPI 01). J Clin Oncol,2003,21:3479-3482.
  • 10El-Rayes BF, Shields AF, Zalupski M, et al. A phase Ⅱ study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol,2005,28:152-156.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部